10 Best Growth Stocks to Buy According to Billionaires

8. argenx SE (NASDAQ:ARGX)

3-Years Sales Growth: 62.05%

Number of Hedge Fund Holders: 47

Number of Billionaires: 9

Value of Billionaire Holdings: $810,790,522

argenx SE (NASDAQ:ARGX) is another best growth stock to buy according to billionaires. It operates as a biopharmaceutical company engaged in developing antibody therapy to treat and serve autoimmune diseases and certain cancers. The company sets itself apart from its competitors by the use of its proprietary Simple Antibody discovery platform, which leverages unique characteristics of the llama immune system to create differentiated therapeutic antibodies.

On April 11, Akash Tewari, an analyst from Jefferies, maintained the Buy rating on the stock with a price target of $772. The analyst based his rating on recent developments for argenx SE (NASDAQ:ARGX) including the FDA’s approval of Vyvgart Hytrulo’s pre-filled syringe for at-home self-injection is a significant milestone. This is particularly unique as it allows patients a more convenient treatment without the need to go to a hospital. This is anticipated to increase the market reach for the drug. Moreover, management anticipates that the increase in price and the expected growth of gross to net will be balanced by the volume growth. argenx SE (NASDAQ:ARGX) also plans to launch an auto-injector which will further strengthen its position in the gMG and CIDP markets.

Artisan Small Cap Fund stated the following regarding Argenx SE (NASDAQ:ARGX) in its Q4 2024 investor letter:

“We ended our investment campaigns in Argenx SE (NASDAQ:ARGX), Tyler Technologies and Interparfums. Shares of Argenx have continued their year-to-date ascent due to multiple positive developments, including FDA approval to promote VYVGART® for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and strong sales execution of VYVGART®’s first approved indication in myasthenia gravis. While we continue to have high conviction, the company has outgrown our small-cap mandate, and we exited our position after a successful multiyear investment campaign.”